Passage Bio Stock News

Passage Bio, Inc. (PASG) CEO Bruce Goldsmith on Q4 2021 Results - Earnings Call Transcript

Passage Bio press release (PASG): Q4 GAAP EPS of -$0.95 misses by $0.06.Q4 cash equivalents $315.8M

PHILADELPHIA, March 03, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided recent business highlights.

Companies Reporting Before The Bell • Travelzoo (NASDAQ: TZOO ) is expected to report quarterly earnings at $0.13 per share on revenue of $18.23 million. • Urban One (NASDAQ: UONEK ) is likely to report earnings for its fourth quarter. • Tile Shop Holdings (NASDAQ: TTSH ) is likely to report earnings for its fourth quarter. • Oxford Square Capital (NASDAQ: OXSQ ) is estimated to report quarterly earnings at $0.09 per share on revenue of $10.30 million. • Aurora Mobile (NASDAQ: JG ) is projected to report quarterly loss at $0.07 per share on revenue of $15.65 million. • Mobile TeleSystems (NYSE: MBT ) is estimated to report quarterly earnings at $0.19 per share on revenue of $1.69 billion. • LENSAR (NASDAQ: LNSR ) is estimated to report quarterly loss at $0.52 per share on revenue of $8.70 million. • Bluegreen Vacations (NYSE: BVH ) is likely to report quarterly earnings at $0.62 per share on revenue of $203.89 million. • Fulcrum Therapeutics (NASDAQ: FULC ) is projected to report quarterly loss at $0.

Passage Bio Inc. (NASDAQ:PASG) concluded the trading at $3.44 on Friday, February 25 with a rise of 6.17% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $3.24 with its price kept floating in the range of $3.18 and $3.44 on the … Analysts Offer Important Insight On Passage Bio Inc. (PASG) Read More »

PHILADELPHIA, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system d

Both children with late infantile GM1 gangliosidosis in Cohort 1 of the Imagine-1 clinical trial showed developmental improvement in assessments by study investigators and caregivers Interim safety data at three and nine months in Imagine-1 showed low dose PBGM01 well tolerated with no serious adverse events reported and no evidence of dorsal root ganglion toxicity First patients dosed in Cohort 2 (late infantile with high dose PBGM01) and Cohort 3 (early infantile with low dose PBGM01); anticipate reporting initial biomarker and safety data in 2H2022 Management to host conference call and webcast on Friday, February 11 at 1 p.m. ET PHILADELPHIA, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG ), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today presented updated clinical data from Imagine-1, a Phase 1/2 study of PBGM01, a gene therapy for GM1 gangliosidosis (GM1). The platform presentation at the 18th Annual WORLD Symposium included clinical assessments of development milestones for Cohort 1 (two patients with late infantile GM1 who were administered a low dose of PBGM01).

Passage Bio Inc (PASG) shares closed today at 0.4% above its 52 week low of $4.77, giving the company a market cap of $259M. The stock is currently down 24.6% year-to-date, down 79.0% over the past 12 months, and down 78.4% over the past five years. This week, the Dow Jones Industrial Average fell 4.6%, and the S&P 500 fell 5.8%. Trading Activity Trading volume this week was 8.3% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.4. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 626.7% The company's stock price performance over the past 12 months lags the peer average by 689.0% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Passage Bio Inc (PASG) shares closed today at 0.5% above its 52 week low of $5.59, giving the company a market cap of $304M. The stock is currently down 11.5% year-to-date, down 79.5% over the past 12 months, and down 74.7% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 35.4% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.3. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 4311.3% The company's stock price performance over the past 12 months lags the peer average by 971.5% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Passage Bio Inc (PASG) shares closed today at 0.5% above its 52 week low of $5.59, giving the company a market cap of $304M. The stock is currently down 11.5% year-to-date, down 80.0% over the past 12 months, and down 74.7% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 35.4% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.3. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 4311.3% The company's stock price performance over the past 12 months lags the peer average by 814.1% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Passage Bio Inc (PASG) shares closed 3.6% lower than its previous 52 week low, giving the company a market cap of $333M. The stock is currently down 2.8% year-to-date, down 78.1% over the past 12 months, and down 72.2% over the past five years. This week, the Dow Jones Industrial Average rose 1.1%, and the S&P 500 rose 0.1%. Trading Activity Trading volume this week was 25.2% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.3. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -305.2% The company's stock price performance over the past 12 months lags the peer average by 1196.8% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.